Advokatfirman Lindahl acts as an adviser in Abboxia’s merger with FrostPharma
Advokatfirman Lindahl represented the sellers of Abboxia in the strategic merger with FrostPharma. The two companies are now merging under the name of FrostPharma and will thus become one of the leading specialist pharmaceutical companies with the widest range of hospital drugs in the Nordic Region.
The merger combines FrostPharma’s commercial strength and strategic alliances with Abboxia’s development capacity, thus allowing more extensive supply of hospital medicines to Nordic healthcare providers.
The Lindahl team consisted of Svante Liljedahl, Olivia Sandin and Jannica Stefansson.
About FrostPharma and Abboxia
FrostPharma, which was founded in 2016, focuses on strategic partnerships and commercialisation of specialist pharmaceuticals in the Nordic market. Abboxia, which was founded in 2017, has developed several specialist medicines for the hospital segment in the Nordic Region.
Read more in the FrostPharma press release here.
Carousel items
-
Cases and transactions
11/18/2025
Lindahl advises Clas Ohlson on acquisition of Phonelife and Reservdelaronline
Clas Ohlson strengthens offering in technology, accessories and spare parts – acquires Phonelife and Reservdelaronline.
-
News articles
11/12/2025
Joel Sunnerman new partner in M&A and Private Equity at Lindahl
Lindahl is strengthening its offering in Corporate M&A and Private Equity by welcoming Joel Sunnerman as a new partner at the Stockholm office.
-
Knowledge
11/10/2025
How to turn sustainability requirements into business advantages in the real estate sector
How to turn new sustainability and regulatory requirements in the real estate sector into business advantages. Read about eight concrete steps that strengthen values, financing and competitiveness.
-
Portraits
11/7/2025
Capital markets and public M&A at Lindahl: Expertise, working environment and range
Read about how Monica Lagercrantz and Lindahl's experts in capital markets and public M&A support companies with stock exchange listings, new share issues and ongoing advice – with expertise, range and a working environment that makes a difference.
-
Read more news and insights?
